Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06468215
Other study ID # 2023G2ECFerSp
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 2024
Est. completion date October 2028

Study information

Verified date June 2024
Source Peking University People's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different populations to optimize the positive impact of clinical interventions. Fertility-sparing therapies (FST) are gaining popularity for early-stage, low-grade endometrial cancer due to mounting evidence supporting favorable oncologic and pregnancy outcomes. However, consensus regarding the feasibility of fertility-sparing therapy for similar low-risk grade-2 endometrioid adenocarcinoma remains elusive. Given the uncertainties surrounding fertility-preserving therapy in patients with moderately differentiated endometrial cancer, this study aims to investigate the optimal regimen of fertility-preserving therapy for patients with IAG2.


Description:

This study aims to explore effective treatment options and pregnancy outcomes for G2 EC patients who wish to preserve their fertility. It compares the efficacy of monotherapy with progesterone versus combined therapy to determine the best treatment option. This study is a multi-center, prospective, randomized controlled trial that collects hospital and outpatient records of uterine endometrioid adenocarcinoma patients who undergo fertility-sparing treatment at 10 units from October 2022. The basic items specified in the study are registered. Selection criteria: Pathological diagnosis of endometrioid adenocarcinoma G2, MRI or ultrasound confirmed localization of the lesion within the endometrium, FIGO (FIGO, 2009) staging IA, age ≤ 45 years, and those who wish to preserve reproductive function, signed informed consent. Exclusion criteria: Tumor invasion of the muscle layer, FIGO (FIGO, 2009) staging IB or higher, tumor differentiation as G1, G3, or non-endometrioid adenocarcinoma, coexistence of malignant tumors in other sites, contraindications or drug prohibitions for conservative treatment, or judged by the investigator to be unsuitable for childbearing. Exclusion criteria: Violation of the treatment protocol; failure to take medication as prescribed, affecting the judgment of drug efficacy; incomplete data affecting the judgment of efficacy and safety. Withdrawal criteria: Intolerance of the used drugs or the appearance of serious complications, including venous or arterial thromboembolism, liver failure, renal failure, anaphylaxis, uterine perforation, etc.; no response to treatment or disease progression during drug therapy; when the patient requests termination of treatment. Treatment Plan: The treatment plan was randomly divided into two groups. Group 1 was a single-drug treatment plan, with oral MPA 500mg/d or MA 320mg/d; Group 2 was a combined treatment plan, with oral MPA 500mg/d/MA 320mg/d combined with the placement of levonorgestrel intrauterine system (LNG-IUS) in the uterus. Since the treatment began, each 3-6 months is a course. At the end of each course, an endometrial biopsy is performed under hysteroscopy to conduct tissue pathological examination and evaluate the treatment effect. A vaginal color Doppler ultrasound is performed every month, and a pelvic MRI is re-evaluated as needed. Additionally, a side effect assessment is performed for each course, including weight, vaginal bleeding, breast discomfort, gastrointestinal symptoms, liver and kidney function, and thrombosis. The efficacy assessment is divided into the following categories: (1) Complete Response (CR), (2) Partial Response (PR), (3) Disease Unresponsive or Stable Disease (NC/SD), (4) Disease Progression (PD), and (5) Relapse. The main measurement indicator is the time required for the first complete remission. The secondary measurement indicators are the one-year complete remission rate, the two-year disease recurrence rate, the cumulative pregnancy rate, pregnancy duration, pregnancy outcomes, changes in serum indicators, and pathological markers.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 16
Est. completion date October 2028
Est. primary completion date July 2028
Accepts healthy volunteers No
Gender Female
Age group N/A to 45 Years
Eligibility Inclusion Criteria: - Endometrioid adenocarcinoma G2, diagnosis by pathological. - The lesion is limited to the endometrium. - FIGO (2009) staging is IA. - Age less than 45. - Strongly request to preserve fertility. - Sign informed consent. Exclusion Criteria: - The tumor has invaded the muscle layer. - FIGO (2009) stage IB or higher. - Endometrioid adenocarcinoma G1, G3, or non-endometrioid cancer - There are malignant tumors in other systems. - Have contraindications for conservative treatment or drug use. - Have been judged by the researcher to be unsuitable for childbearing.

Study Design


Intervention

Drug:
Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.
Compare the efficacy of mono-therapy with progesterone versus combined therapy to determine the best treatment option.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Peking University People's Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary The Time Required for Complete Remission for the First Time The time from the diagnosis of G2 endometrioid carcinoma to the first complete remission after fertility-preserving treatment.(year) 5 years
Secondary One-year complete remission rate The percentage of patients who achieved complete remission after one year of fertility preservation treatment. 5 years
Secondary two-year disease recurrence rate The probability of recurrence within 2 years for patients who underwent treatment for preserving fertility and achieved complete remission. 5 years
Secondary cumulative pregnancy rate The percentage of pregnancies that occurred during the observation period. 5 years
Secondary pregnancy outcome The pregnancy outcomes in women who successfully conceived after undergoing fertility-sparing treatment. They can be categorized as: full-term delivery; premature delivery; miscarriage; stillbirth. 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Recruiting NCT06074796 - The Determinants of Fertility Preservation in TRANSgender Patients.
Completed NCT01448460 - Oocyte Vitrification for In Vitro Fertilization (IVF) Patients and Women With Fertility Threatening Conditions N/A
Recruiting NCT02400827 - Contamination of Ovarian Tissue by RT-PCR in Participants With Solid Tumors N/A
Recruiting NCT02400970 - Contamination of Testicle Tissue by RT-PCR in Participants With Solid Tumors N/A
Recruiting NCT02895165 - PREgnancy and FERtility Registry
Not yet recruiting NCT03725280 - Micro RNA Profile in the Ovarian Follicle Fluid of Transgender Men
Recruiting NCT04904263 - Advisory Board on Cancer, Infertility and Pregnancy
Not yet recruiting NCT06289062 - Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer Phase 2
Not yet recruiting NCT06289751 - Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer Phase 2
Completed NCT01696786 - Oocyte Cryopreservation N/A
Recruiting NCT05372549 - Correlation of Oxidative Stress and Oocyte Quality in Fertility Preservation N/A
Completed NCT01645241 - Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation N/A
Completed NCT01160315 - Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure Phase 2/Phase 3
Not yet recruiting NCT06175832 - PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study Phase 4
Active, not recruiting NCT00827476 - Improving Human Ovarian Transplantation Phase 0
Completed NCT00380406 - PROtecting Ovaries and Fertility During Chemotherapy - The PROOF Trial Phase 3
Active, not recruiting NCT03817814 - Decisions of Young Women With Breast Cancer Regarding Fertility Preservation Before Cancer Treatment and Family Building After Treatment
Recruiting NCT05443737 - Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients Phase 3
Completed NCT05100498 - Web-based Oncofertility Support Tool for Reproductive-age Women With Breast Cancer N/A